Login / Signup

Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review.

Nikolas RufferMarie-Therese HolzerLukas Can BalSimon MelderisMartin KruscheTobias B HuberIna Koetter
Published in: Rheumatology international (2022)
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal acquired thrombotic microangiopathy syndrome that frequently develops in the context of infectious diseases or systemic autoimmune conditions including connective tissue diseases. We report the case of a 42-year-old female suffering from severe iTTP associated with anti-Jo-1 positive antisynthetase syndrome, which was successfully treated with combination therapy of intravenous immune globulin, rituximab and plasma exchange. Based on a systematic review of the literature, two additional cases of idiopathic inflammatory myopathy-associated iTTP (secondary iTTP) were identified. In conclusion, iTTP may be a rare complication of IIM that clinicians should consider in cases of marked thrombocytopenia. Further work-up of this finding should include a peripheral blood smear (schistocyte count) and ADAMTS13 activity. The concomitant manifestation of these autoimmune conditions may require intensive immunosuppressive therapy.
Keyphrases
  • combination therapy
  • peripheral blood
  • infectious diseases
  • late onset
  • multiple sclerosis
  • drug induced
  • oxidative stress
  • case report
  • early onset
  • high dose
  • pulmonary tuberculosis
  • muscular dystrophy
  • bone marrow